Industry / Germany
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Big Opportunities For API Inspection Firms
June 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
BMI believes there is significant global growth potential for third party active pharmaceutical ingredient (API) inspection firms over the next few years. This is in light of the fact that multinational pharmaceutical companies are increasingly outsourcing production abroad, numbers of counterfeit pharmaceuticals appear to be on the rise, and there are growing concerns over the quality of drugs produced in less developed